Encorafenib + Cetuximab with FOLFIRI after progression
Part of Cancer, Digestive system clinical trials.
This trial tests adding a new chemotherapy regimen (FOLFIRI) to the combination of Encorafenib and Cetuximab for people with a specific type of advanced colorectal cancer that has started growing again after initial treatment with Encorafenib and Cetuximab. The goal is to see if the new combination can help control the cancer longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a specific genetic change in your tumor called BRAF V600E.
- Your cancer has spread to other parts of the body (metastatic).
- You have already been treated with Encorafenib and Cetuximab, and your cancer grew while on that treatment.
- Your cancer either shrank or stayed stable for at least 3 months on that previous treatment.
- You are generally well enough to get around and take care of yourself (ECOG performance status 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a combination of two targeted drugs (encorafenib and cetuximab) with standard chemotherapy before surgery in people with a specific type of colorectal cancer that has the BRAF V600E mutation and is locally advanced or has limited spread. The goal is to see if this treatment can shrink tumors and improve outcomes.
This trial tests whether giving encorafenib and cetuximab before surgery can shrink or control BRAF-mutated colon or upper rectal cancer and make surgery more effective. It also checks whether this approach is safe and helps patients do better overall.
This trial tests a combination of four drugs (irinotecan liposome, fluorouracil, folinic acid, vermofenib, and cetuximab) as a first treatment for people with advanced colorectal cancer that has a specific BRAF V600E mutation. It aims to see if this combination can shrink tumors or slow their growth.
This trial tests whether a combination chemotherapy (Folfiri) plus cetuximab works better for people with stage IV colorectal cancer that has specific tumor gene markers and a specific blood-gene type. It may help you shrink tumors or control the cancer if you match the study’s required lab and health criteria.
This trial tests a new combination of drugs for people with advanced colorectal cancer that has a specific genetic change called BRAF V600E. The treatment includes a targeted therapy (ivosidenib) plus chemotherapy and a pain-relief drug (celecoxib). It is for people whose cancer has stopped responding to previous treatments, including BRAF-targeted therapies.
This trial tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy and a targeted therapy (cetuximab) as the first treatment for colorectal cancer that has come back or spread. The goal is to see if this combination can shrink tumors and help patients live longer.
Hear when a new Colorectal Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.